Full Year 2023 Investor Presentation
Novo NordiskⓇ
156
Investor presentation Full year 2023
In 2023, more than 6.7 million people with diabetes were reached
with access and affordability initiatives.
6.7 out of 40.5 million people were reached
with access and affordability initiatives
Million patients
Access to
Insulin
Commitment
A number of focused programmes (as of full year 2023)
3 USD ceiling price for human insulin vial offered to 77 low- and middle-
income countries, reaching 2.4 million patients in 2023
2.6 million patients reached at or below the ceiling price in countries
outside the commitment¹
1.
2.
40.5
6.7
34.9
Patients reached in 2023
J
Changing
Diabetes® in
Children²
52,249 children reached at the end of 2023, across 29 countries More than
half of the newly enrolled children reached through expansion in Asian
countries mainly India, Pakistan, Indonesia and Vietnam
Vulnerability
assessments
•
Ensure access and affordable insulin and strengthen comprehensive
diabetes care for vulnerable population groups
There are currently 22 active Affordability Plans in 20 countried across,
APAC, LATAM and SEEMEA regions based om completed vulnerability
assessments
US
affordability
offerings
In 2023, DKK 358 billion were provided in discounts and rebates in the US,
amounting to 74% of US gross sales
The access and affordability programmes are not mutually exclusive, implying that the sum of the reach of each programme cannot be interpreted as the total unique number of people with diabetes reached. More info on Novo Nordisk access and
affordability programmes can be found at: Access & affordability (novonordisk.com).
Changing Diabetes® in Children is a public-private partnership between the International Society for Paediatric and Adolescent Diabetes, the World Diabetes Foundation, Roche, and Novo Nordisk.View entire presentation